High-rolling investors have positioned themselves bearish on Pfizer PFE, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Pfizer. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $64,200, and 9 calls, totaling $566,920.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $28.0 for Pfizer over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $20.0 to $28.0 in the last 30 days.
Pfizer Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | CALL | TRADE | BEARISH | 06/20/25 | $1.18 | $1.17 | $1.17 | $28.00 | $171.7K | 36.1K | 1.6K |
| PFE | CALL | SWEEP | BEARISH | 01/17/25 | $0.35 | $0.31 | $0.33 | $27.00 | $78.2K | 10.4K | 3.2K |
| PFE | CALL | TRADE | BEARISH | 01/15/27 | $7.6 | $6.95 | $7.0 | $20.00 | $70.0K | 5.9K | 1 |
| PFE | CALL | SWEEP | BULLISH | 01/15/27 | $7.2 | $7.15 | $7.2 | $20.00 | $68.2K | 5.9K | 107 |
| PFE | PUT | TRADE | BEARISH | 01/17/25 | $1.07 | $0.87 | $1.07 | $28.00 | $64.2K | 190 | 0 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Current Position of Pfizer
- Currently trading with a volume of 13,755,318, the PFE's price is down by -1.46%, now at $26.73.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 27 days.
Professional Analyst Ratings for Pfizer
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $30.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $29. * An analyst from Truist Securities persists with their Buy rating on Pfizer, maintaining a target price of $32. * Maintaining their stance, an analyst from Guggenheim continues to hold a Buy rating for Pfizer, targeting a price of $33. * An analyst from B of A Securities downgraded its action to Neutral with a price target of $29.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
